NYSE:BAX Baxter International (BAX) Stock Price, News & Analysis $36.17 -0.05 (-0.14%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$36.04▼$36.5050-Day Range$32.85▼$37.4252-Week Range$31.01▼$44.01Volume2.58 million shsAverage Volume4.27 million shsMarket Capitalization$18.43 billionP/E Ratio6.96Dividend Yield3.21%Price Target$41.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Baxter International alerts: Email Address Baxter International MarketRank™ Stock AnalysisAnalyst RatingHold2.09 Rating ScoreUpside/Downside15.4% Upside$41.73 Price TargetShort InterestHealthy1.95% of Shares Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-1.95Upright™ Environmental ScoreNews Sentiment0.59Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth9.28%From $2.91 to $3.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.77 out of 5 starsMedical Sector42nd out of 924 stocksSurgical & Medical Instruments Industry10th out of 97 stocks 3.0 Analyst's Opinion Consensus RatingBaxter International has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageBaxter International has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Baxter International's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.95% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently increased by 12.20%, indicating that investor sentiment is decreasing significantly. Previous Next 2.5 Dividend Strength Dividend YieldBaxter International pays a meaningful dividend of 3.25%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthBaxter International does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Baxter International is 22.31%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 36.48% next year. This indicates that Baxter International will be able to sustain or increase its dividend.Read more about Baxter International's dividend. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBaxter International has received a 55.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Vaccines (J07)", "Blood plasma proteins", and "Anaesthetics (N01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Baxter International is -1.95. Previous Next 3.1 News and Social Media Coverage News SentimentBaxter International has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Baxter International this week, compared to 7 articles on an average week.Search Interest45 people have searched for BAX on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.MarketBeat Follows8 people have added Baxter International to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of Baxter International is held by insiders.Percentage Held by Institutions90.19% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Baxter International's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Baxter International are expected to grow by 9.28% in the coming year, from $2.91 to $3.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 6.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 6.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.34.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Baxter International's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. About Baxter International Stock (NYSE:BAX)Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.Read More BAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BAX Stock News HeadlinesAugust 19 at 3:36 AM | americanbankingnews.comBaxter International Inc. (NYSE:BAX) Receives $41.73 Consensus PT from AnalystsAugust 19 at 1:05 AM | americanbankingnews.comBaxter International Inc. (NYSE:BAX) Short Interest Up 12.2% in JulyAugust 22, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 16, 2024 | marketwatch.comBaxter International Inc. stock underperforms Friday when compared to competitors despite daily gainsAugust 13, 2024 | msn.comBaxter to sell its kidney-care business in a $3.8 billion deal to Carlyle GroupAugust 13, 2024 | markets.businessinsider.comBaxter Agrees To Sell Its Kidney Care Segment To Carlyle For $3.8 BlnAugust 13, 2024 | markets.businessinsider.comBaxter International Hold Rating Maintained Amidst Modest Growth Projections Post-Vantive SaleAugust 13, 2024 | msn.comBaxter to divest kidney care segment to Carlyle for $3.8BAugust 22, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 13, 2024 | investopedia.comBaxter Stock Falls After it Unloads Kidney Care Division in $3.8B DealAugust 12, 2024 | americanbankingnews.comThe Goldman Sachs Group Raises Baxter International (NYSE:BAX) Price Target to $40.00August 9, 2024 | markets.businessinsider.comBaxter International: Growth Prospects & Margin Expansion Post-Renal Sale – Hold Rating MaintainedAugust 9, 2024 | marketwatch.comBaxter International Inc. stock underperforms Wednesday when compared to competitorsAugust 9, 2024 | finance.yahoo.comBaxter International Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 8, 2024 | msn.comBaxter Recalls Heparin Sodium Injection Over Elevated Endotoxin LevelsAugust 8, 2024 | benzinga.comThe Latest Analyst Ratings For Baxter IntlAugust 8, 2024 | msn.comBaxter International (BAX) Slipped in Q2 Despite Solid Results and Guidance RaiseAugust 7, 2024 | seekingalpha.comBaxter: Reiterating Our Buy Rating After A Promising Q2See More Headlines Receive BAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/1 Dividend5/31/2024Dividend Payable7/01/2024Last Earnings8/06/2024Today8/21/2024Ex-Dividend for 10/1 Dividend8/30/2024Dividend Payable10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:BAX CUSIP07181310 CIK10456 Webwww.baxter.com Phone(224) 948-2000Fax224-948-1813Employees60,000Year Founded1931Price Target and Rating Average Stock Price Target$41.73 High Stock Price Target$54.00 Low Stock Price Target$30.00 Potential Upside/Downside+15.4%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio6.96 Forward P/E Ratio12.43 P/E Growth1.88Net Income$2.66 billion Net Margins17.79% Pretax Margin-0.01% Return on Equity18.47% Return on Assets4.91% Debt Debt-to-Equity Ratio1.35 Current Ratio1.48 Quick Ratio1.01 Sales & Book Value Annual Sales$15.00 billion Price / Sales1.23 Cash Flow$5.26 per share Price / Cash Flow6.87 Book Value$16.69 per share Price / Book2.17Miscellaneous Outstanding Shares509,580,000Free Float508,510,000Market Cap$18.43 billion OptionableOptionable Beta0.57 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jose E. Almeida (Age 62)Chairman of the Board, President & CEO Comp: $3.62MMr. Joel T. Grade (Age 53)Executive VP & CFO Comp: $829.82kMs. Heather Knight (Age 52)Executive VP & Group President of Medical Products and Therapies Comp: $1.63MMr. Alok Sonig B.E. (Age 52)Mba, Executive VP & Group President of Pharmaceuticals Comp: $1.56MMr. Christopher A. Toth (Age 44)Executive VP & Group President of Kidney Care Comp: $5.26MMs. Tobi Karchmer M.D.M.S., Senior VP and Chief Medical & Scientific OfficerMs. Clare TrachtmanVice President of Investor RelationsMr. David S. Rosenbloom (Age 64)Executive VP & General Counsel Comp: $776.51kMs. Stacey Eisen?Senior Vice President, Chief Communications Officer & Corporate Marketing?Ms. Jeanne K. Mason Ph.D. (Age 68)?Executive VP & Chief Human Resources Officer Comp: $1.99MMore ExecutivesKey CompetitorsBecton, Dickinson and CompanyNYSE:BDXEdwards LifesciencesNYSE:EWIDEXX LaboratoriesNASDAQ:IDXXResMedNYSE:RMDDexComNASDAQ:DXCMView All CompetitorsInstitutional OwnershipSkyView Investment Advisors LLCBought 1,248 shares on 8/16/2024Ownership: 0.002%Toronto Dominion BankSold 3,031 shares on 8/15/2024Ownership: 0.029%Millennium Management LLCBought 59,500 shares on 8/15/2024Ownership: 0.000%Cubist Systematic Strategies LLCSold 8,800 shares on 8/14/2024Ownership: 0.000%Point72 DIFC LtdSold 19,100 shares on 8/14/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Baxter International Stock? BAX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Baxter International Inc.: Baxter International Inc. develops and provides a portfolio of healthcare products worldwide, which is a growing industry with increasing demand for healthcare services. The company operates through multiple segments, including Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care, providing diversification in revenue streams. Recent developments in the healthcare industry have shown a trend towards innovation and technological advancements, which Baxter International Inc. is well-positioned to capitalize on. Baxter International Inc. has a strong track record of product development and innovation, which can lead to competitive advantages in the market. With the current stock price of Baxter International Inc., investors have the opportunity to invest in a company with growth potential at a reasonable valuation. Cons Investors should be bearish about investing in Baxter International Inc. for these reasons: While the healthcare industry is growing, it is also highly regulated and subject to changes in government policies, which can impact the company's operations and profitability. Competition in the healthcare sector is intense, with many established players and new entrants vying for market share, which could potentially affect Baxter International Inc.'s market position. Investing in healthcare companies can be risky due to factors such as regulatory approvals, product recalls, and litigation risks, which could negatively impact the company's financial performance. Fluctuations in healthcare spending and reimbursement rates can affect Baxter International Inc.'s revenue and profitability, making it susceptible to economic downturns and changes in healthcare policies. While Baxter International Inc. has a strong track record, past performance is not indicative of future results, and investors should carefully consider the risks associated with investing in the company. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com. BAX Stock Analysis - Frequently Asked Questions How have BAX shares performed this year? Baxter International's stock was trading at $38.66 on January 1st, 2024. Since then, BAX stock has decreased by 6.4% and is now trading at $36.17. View the best growth stocks for 2024 here. How were Baxter International's earnings last quarter? Baxter International Inc. (NYSE:BAX) issued its quarterly earnings data on Tuesday, August, 6th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. The business's revenue for the quarter was up 2.8% compared to the same quarter last year. Read the conference call transcript. What is José (Joe) Almeida's approval rating as Baxter International's CEO? 506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees. Does Baxter International have any subsidiaries? Baxter International subsidiaries include Cheetah Medical, ApaTech Limited, Baxter AO, Baxter Belgium SPRL, Baxter (China) Investment Co. Ltd, Baxter Company Ltd, Baxter Corporation (Canada), and more. Who are Baxter International's major shareholders? Baxter International's top institutional shareholders include Bank of New York Mellon Corp (1.33%), LSV Asset Management (0.82%), Shapiro Capital Management LLC (0.64%) and Thompson Siegel & Walmsley LLC (0.39%). Insiders that own company stock include Jeanne K Mason, Albert P L Stroucken, Jacqueline Kunzler and Brian Stevens. View institutional ownership trends. How do I buy shares of Baxter International? Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baxter International investors own include Xtrackers California Municipal Bond ETF (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC) and Abbott Laboratories (ABT). This page (NYSE:BAX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baxter International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baxter International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BAX Stock Alerts